Xentria Inc. has recently announced they received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for their intravenous TNF-inhibitor, XTMAB-16. The FDA grants orphan status to drugs being developed to treat those with rare diseases. This...
Program supports specialized skill development of early-career physicians and researchers interested in studying sarcoidosis CHICAGO, Dec. 17, 2020 /PRNewswire/ — The Foundation for Sarcoidosis Research (FSR) is pleased to announce the opening of a new...
This is a recording from FSR’s COVID-19 Q&A with Dr. Divya Patel on December 10, 2020. Topics covered include how COVID-19 may affect sarcoidosis patients, the new vaccines*, and holiday safety. *Please see below for a note from Dr. Divya Patel as a followup...
As part of FSR’s continued Wellness Series, we are excited to support sarcoidosis warriors and their care partners through our Beginning Qi Gong (Chee-Gung) Workshop Series. If you attended one of our Summits, you may have seen our Intro to Qi Gong video. And if you...
